Semaglutide vs Tirzepatide vs Retatrutide

Semaglutide vs Tirzepatide vs Retatrutide — how these GLP-1-class research peptides compare by receptor targets and research focus. Research Use Only.

Semaglutide vs Tirzepatide vs Retatrutide at a glance

Semaglutide Tirzepatide Retatrutide
Class / mechanism GLP-1 receptor agonist (single incretin receptor) Dual GLP-1 / GIP receptor agonist Triple GLP-1 / GIP / glucagon receptor agonist
Sequence
CAS number 2381306-68-7
Research focus GLP-1 receptor binding, metabolic signaling, cardiovascular cell models Dual incretin-receptor signaling, metabolic modulation Triple-receptor signaling; metabolic, adipose, hepatocyte, cardiovascular models
Form Lyophilized powder Lyophilized powder Lyophilized powder
Storage -20°C, protected from light -20°C, protected from light -20°C, protected from light

What’s the difference?

The three differ by how many incretin and metabolic receptors they engage. Semaglutide is a single GLP-1 receptor agonist; Tirzepatide is a dual agonist that adds the GIP receptor; and Retatrutide is a triple agonist that further adds the glucagon receptor. In laboratory research they are used as reference agonists of increasing receptor breadth.

Which to use in research

Choose the compound whose receptor coverage matches the pathway under study: Semaglutide for GLP-1-only questions, Tirzepatide for combined GLP-1/GIP questions, and Retatrutide where glucagon-receptor involvement is also of interest. All three are supplied lyophilised and reconstituted identically.

Handling

All are supplied as lyophilised powder for reconstitution in bacteriostatic or sterile water. See the reconstitution guide and calculator. Each lot ships with a lot-specific Certificate of Analysis.

Learn more

Read the individual overviews: Semaglutide research overview · Tirzepatide research overview · Retatrutide research overview.

Buy for research

Frequently asked questions

What is the difference between semaglutide, tirzepatide and retatrutide?

They differ by receptor targets: semaglutide is a single GLP-1 agonist, tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist.

Which engages the most receptors?

Retatrutide, as a triple GLP-1/GIP/glucagon receptor agonist, engages the broadest set of these receptors in research models.

Part of our research peptides handbook.

Research Use Only. This information is provided for educational purposes for qualified researchers. All products are sold strictly for in-vitro laboratory research and development — not for human or animal use, and not intended to diagnose, treat, cure, or prevent any disease.